Nogapendekin Alfa Inbakicept-Pmln: uses, dosing, side effects & brands
Nogapendekin Alfa Inbakicept-Pmln is an interleukin-15 receptor agonist sold in the U.S. under one brand, for urinary bladder neoplasms. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Interleukin-15 Receptor Agonist
- Treats
- Urinary Bladder Neoplasms
- Available as
- Solution
- Sold as
- Anktiva
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How nogapendekin alfa inbakicept-pmln is dosed
From the FDA label for Anktiva (application BLA761336). Other nogapendekin alfa inbakicept-pmln products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
For Intravesical Use Only For induction: 400 mcg administered intravesically with BCG once a week for 6 weeks. A second induction course may be administered if complete response is not achieved at month 3. ( 2.1 ) For maintenance: 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19. For patients with an ongoing complete response at month 25 and later, additional maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37. ( 2.1 ) Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. ( 2.2 ) See full Prescribing Information for dilution and administration instructions. 2.1 Recommended Dosage For Intravesical Use Only. Do NOT administer by subcutaneous or intravenous or intramuscular routes. For induction: ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks. A second induction course may be administered if complete response is not achieved at month 3. For maintenance: After BCG and ANKTIVA induction therapy, ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses). For patients with an ongoing complete response at month 25 and later,…
Nogapendekin Alfa Inbakicept-Pmln side effects
The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. at toll-free phone 877-265-8482 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ANKTIVA with BCG was evaluated in Cohort A of QUILT-3.032, a single-arm, multicenter clinical study in 88 patients with BCG-unresponsive high-grade NMIBC with CIS with or without Ta/T1 papillary disease [see Clinical Studies ( 14 )]. Patients received 400 mcg ANKTIVA with BCG weekly for 6 consecutive weeks during induction and then once a week for every 3 weeks at 4, 7, 10, 13, and 19 months for patients with no or low grade disease. Patients with persistent CIS or high grade Ta at 3 months were eligible to receive a second induction. Patients with ongoing CR at 25 months were eligible to receive additional…
Who shouldn’t take nogapendekin alfa inbakicept-pmln
None None ( 4 )
Every nogapendekin alfa inbakicept-pmln product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Anktiva.
What people report to the FDA about nogapendekin alfa inbakicept-pmln
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1 reports naming nogapendekin alfa inbakicept-pmln, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- blood creatinine increased1 reports
- confusional state1 reports
- hyponatraemia1 reports
- mental status changes1 reports
- therapy cessation1 reports
Read these as a signal, not a rate. A report does not mean nogapendekin alfa inbakicept-pmln caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is nogapendekin alfa inbakicept-pmln?
Nogapendekin alfa inbakicept-pmln is an interleukin-15 (IL-15) receptor agonist. It is a soluble complex consisting of (a) nogapendekin alfa (a human IL-15N72D variant, 114 amino acids) bound to (b) inbakicept [a dimeric human IL-15Rα sushi domain (65 amino acids)/human IgG1 Fc fusion protein (232 amino acids)]. Each fully assembled nogapendekin alfa inbakicept-pmln complex consists of a single inbakicept and two nogapendekin alfa components. Each IL-15N72D component is bound to one of the IL-15Rα sushi domains.
What kind of drug is nogapendekin alfa inbakicept-pmln?
The FDA classifies nogapendekin alfa inbakicept-pmln as an interleukin-15 receptor agonist. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take nogapendekin alfa inbakicept-pmln with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run nogapendekin alfa inbakicept-pmln against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does nogapendekin alfa inbakicept-pmln come in?
Across the brands we track, nogapendekin alfa inbakicept-pmln is currently marketed as solution, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic nogapendekin alfa inbakicept-pmln?
We do not currently list a generic-labelled nogapendekin alfa inbakicept-pmln product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Nogapendekin Alfa Inbakicept-Pmln: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/nogapendekin-alfa-inbakicept-pmln
- MLA
- “Nogapendekin Alfa Inbakicept-Pmln: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/nogapendekin-alfa-inbakicept-pmln.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for nogapendekin alfa inbakicept-pmln on DailyMed (NIH) ↗.